Anterior|Siguiente

Avances recientes en la investigación clínica sobre el tratamiento del cáncer de ovario con Guizhi Fuling Wan

  • role： First author第一作者
  • Affiliation：

    Heilongjiang University of Chinese Medicine，Harbin 150400，China

  • Email：67913968@qq.com
  • Introduction：关木馨，在读博士，从事中医妇科疾病研究，E-mail：67913968@qq.com
GUAN Muxin1,  
  • Affiliation：

    The First Affiliated Hospital of Heilongjiang University of Chinese Medicine，Harbin 150400，China

FENG Jiaxing2,  
  • Affiliation：

    Heilongjiang University of Chinese Medicine，Harbin 150400，China

ZHU Mengyi1,  
  • Affiliation：

    The First Affiliated Hospital of Heilongjiang University of Chinese Medicine，Harbin 150400，China

WANG Yu2,  
  • role： Corresponding author通信作者
  • Affiliation：

    The First Affiliated Hospital of Heilongjiang University of Chinese Medicine，Harbin 150400，China

  • Email：xiaokewu2002@vip.sina.com
  • Introduction：吴效科，博士，教授，主任医师，博士生导师，从事中医妇科疾病研究，E-mail：xiaokewu2002@vip.sina.com
WU Xiaoke2*

resumen

El cáncer de ovario (OC) es un tumor maligno ginecológico común en la práctica clínica. En las etapas tempranas suele ser asintomático, mientras que en las etapas avanzadas los principales síntomas son distensión abdominal, falta de apetito, dolor abdominal sordo y otros síntomas no específicos. Algunos pacientes pueden presentar pérdida de peso, anemia y otras manifestaciones de caquexia. El diagnóstico temprano es difícil y la tasa de mortalidad es la más alta entre los tumores malignos ginecológicos, lo que representa un gran desafío para el tratamiento clínico. La fórmula clásica de la medicina tradicional china Guizhi Fuling Wan, extraída del "Jinkui Yaolue", tiene efectos para activar la sangre, eliminar la estasis y aliviar los nódulos. En los últimos años, se ha utilizado ampliamente para tratar el OC, con buenos resultados. Este artículo resume la aplicación clínica de la fórmula en el tratamiento del OC desde dos aspectos principales: análisis de la fórmula básica y estudios clínicos. En cuanto a la fórmula básica, posee características de activar la sangre y eliminar la estasis; tratar agua y sangre simultáneamente, disolver nódulos; combinación de calentamiento y enfriamiento,補 y eliminación simultáneas. Mediante el método combinado de "abrir" y "补", ayuda a fortalecer el cuerpo, eliminar la patología y tratar los síntomas subyacentes. En los estudios clínicos, Guizhi Fuling Wan puede aplicarse en todas las etapas del OC, no solo favorece la recuperación postoperatoria, sino que también puede combinarse con quimioterapia, inmunoterapia y otros tratamientos para el tratamiento conjunto del OC avanzado, aumentando la efectividad terapéutica. Además, la fórmula puede aliviar diversas reacciones adversas causadas por la quimioterapia, tiene una alta seguridad, mejora la calidad de vida de los pacientes, prolonga la supervivencia y optimiza el control tumoral. A través de este análisis, el artículo expone el estado actual de la investigación clínica sobre la combinación de Guizhi Fuling Wan con medicamentos occidentales para tratar el OC, proponiendo sugerencias y mejoras para las deficiencias actuales en la investigación clínica, con el fin de proporcionar una referencia para la aplicación clínica de esta fórmula y la construcción de un modelo de tratamiento integrado de medicina china y occidental.

palabra clave

Guizhi Fuling Wan;Cáncer de ovario;Aplicación clínica;Revisión

References

  1. 1.
    SUNG H，FERLAY J，SIEGEL R L，et al.Global Cancer Statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71 （3）：209-249.
  2. 2.
    ZHENG R S，CHEN R，HAN B F，et al.Cancer incidence and mortality in China，2022［J］.Chin J Oncol，2024，46 （3）：221-231.
  3. 3.
    QI J，LI M，WANG L，et al.National and subnational trends in cancer burden in China，2005-20：An analysis of national mortality surveillance data［J］.Lancet Public Health，2023，8 （12）：e943-e955.
  4. 4.
    GONZÁLEZ-MARTÍN A，HARTER P，LEARY A，et al.Newly diagnosed and relapsed epithelial ovarian cancer：ESMO Clinical Practice Guideline for diagnosis，treatment and follow-up［J］.Ann Oncol，2023，34 （10）：833-848.
  5. 5.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology-ovarian cancer including fallopian tube cancer and primary peritoneal cancer NCCN Evidence BlocksTM （2024 Version 3） ［EB/OL］. ［2024-07-15］. .
  6. 6.
    KONG B H，LIU J H，HUANG H，et al.Guidelines for clinical application of PARP inhibitors in ovarian cancer（2022 edition）［J］.Curr Adv Obstet Gynecol，2022，31（8）：561-572.
  7. 7.
    Quality control index for standardized diagnosis and treatment of primary ovarian cancer in China （2022 edition）［J］.Chin J Oncol，2022，44（7）：609-614.
  8. 8.
    ZHOU L P，LEI L，CHU G Q，et al.Effects of cinnamon Twig and poria pill combined with cisplatin on effects of cinnamon Twig and poria pill combined with cisplatin on［J］.Ningxia Med J，2021，43（1）：20-23，97.
  9. 9.
    FENG M，YUAN S，HUANG Y Q，et al.Exploring the effect of Guizhi Fulingwan on ovarian cancer based on network pharmacology and cell experiments［J］.Chin Tradit Pat Med，2023，45（9）：3081-3090.
  10. 10.
    ZHANG W P，LV Q，GUO X J，et al.Mechanism of Guizhi Fuling Wan in regulating metadherin and phosphatase and tensin homologue to reverse multidrug resistance of ovarian cancer［J］.Sci Technol Engin，2018，18（20）：59-63.
  11. 11.
    HAN L，CAO X，CHEN Z，et al.Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract［J］.BMC Complement Med Ther，2020，20 （1）：57.
  12. 12.
    GUO X J，HAN L，YANG L，et al.Guizhi Fuling Wan combined with cisplatin/paclitaxel chemotherapy enhance survival rate of ovarian cancer multidrug resistance tumor-bearing mice［J］.Sci Technol Eng，2016，16（20）：120-124.
  13. 13.
    HAN L，GUO X，BIAN H，et al.Guizhi Fuling Wan，a traditional Chinese herbal formula，sensitizes cisplatin-resistant human ovarian cancer cells through inactivation of the PI3K/Akt/mTOR pathway［J］.Evid Based Complement Alternat Med，2016，2016：4651949.
  14. 14.
    XING L，QU M M，ZHANG X Y.Anti-tumor effects and mechanism of Guizhi Fulingwan on rat ovarian cancer xenografts［J］.Med J West China，2020，32（4）：515-519.
  15. 15.
    WANG Y，GAO H Q.Studies of GFW on inducing apoptosis in ovarian cancer cell lines HO8910［J］.J Mudanjiang Med Univ，2003，24（6）：1-4.
  16. 16.
    YIN H Y，YANG E，LIANG J H，et al.Mechanism study of Guizhi Fulingwan intervention on epithelial ovarian cancer in nude mice［J］.Int J Tradit Chin Med，2016，38（9）：831-836.
  17. 17.
    TIAN Z H，ZHAO D J.The application effect of Guizhi Fuling decoction combined with chemotherapy in postoperative patients with ovarian cancer［J］.Mod Med Health Res Elec J，2022，6（12）：79-82.
  18. 18.
    SONG T T，LIU G Y，WANG Y Y，et al.Effect of Guizhi Fuling decoction（桂枝茯苓汤） on sensitization of postoperative chemotherapy of ovarian cancer and its influence on inflammatory factors and immune indexes of patients［J］.Chin Arch Tradit Chin Med，2021，39（5）：251-254.
  19. 19.
    WANG F F，LI Y P，PU T D，et al.Effects of Guizhi Fuling decoction on peripheral blood T lymphocyte subsets，serum tumor markers in patients with ovarian cancer after operation and coagulation level change［J］.World Chin Med，2019，14（8）：2067-2072.
  20. 20.
    CHEN L.Observation on the clinical effect of acupuncture combined with Guizhi Fuling decoction on postoperative patients with ovarian cancer［J］.Guangming J Chin Med，2020，35（20）：3238-3239.
  21. 21.
    YE Y S，CHEN J Y，LIN Y L，et al.Preliminary evaluation on the efficacy and safety of paclitaxel liposome and paclitaxel combined with carboplatin in the patients with ovarian cancer［J］.Med Innov China，2020，17（6）：129-133.
  22. 22.
    DAI S，LIU K F.Clinical efficacy and safety of Guizhi Fulingwan modified formula as an adjuvant therapy for advanced ovarian cancer［J］.Chin J Clin Ration Drug Use，2021，14（23）：145-147.
  23. 23.
    WANG X M，HUANG J，SHI F，et al.Clinical efficacy of traditional Chinese medicine combined with chemotherapy in the treatment of late stage newly diagnosed ovarian cancer patients and its impact on survival［J］.Guangming J Chin Med，2019，34（24）：3798-3800.
  24. 24.
    LI Y Z.Guizhi Fulingwan combined with western medicine on advanced ovarian cancer［J］.Clin Res，2020，28（5）：130-132.
  25. 25.
    VARGA A，PIHA-PAUL S，OTT P A，et al.Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer：Analysis of KEYNOTE-028［J］.Gynecol Oncol，2019，152 （2）：243-250.
  26. 26.
    MOORE K N，BOOKMAN M，SEHOULI J，et al.Atezolizumab，bevacizumab，and chemotherapy for newly diagnosed stage Ⅲ or Ⅳ ovarian cancer：Placebo-Controlled Randomized Phase Ⅲ Trial （IMagyn050/GOG 3015/ENGOT-OV39）［J］.J Clin Oncol，2021，39 （17）：1842-1855.
  27. 27.
    PIGNATA S，BOOKMAN M，SEHOULI J，et al.Overall survival and patient-reported outcome results from the placebo-controlled randomized phase Ⅲ IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage Ⅲ/Ⅳ ovarian cancer［J］.Gynecol Oncol，2023，177：20-31.
  28. 28.
    MONK B J，COLOMBO N，OZA A M，et al.Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer（JAVELIN Ovarian 100）：An open-label，randomised，phase 3 trial［J］.Lancet Oncol，2021，22（9）：1275-1289.
  29. 29.
    DOMCHEK S M，POSTEL-VINAY S，IM S A，et al.Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer （MEDIOLA）：An open-label，multicentre，phase 1/2，basket study［J］.Lancet Oncol，2020，21 （9）：1155-1164.
  30. 30.
    PAIJENS S T，VLEDDER A，DE BRUYN M，et al.Tumor-infiltrating lymphocytes in the immunotherapy era［J］.Cell Mol Immunol，2021，18 （4）：842-859.
  31. 31.
    PATEL S A，NILSSON M B，LE X，et al.Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy［J］.Clin Cancer Res，2023，29 （1）：30-39.
  32. 32.
    BAGCHI S，YUAN R，ENGLEMAN E G.Immune checkpoint inhibitors for the treatment of cancer：Clinical impact and mechanisms of response and resistance［J］.Annu Rev Pathol，2021，16：223-249.
  33. 33.
    GREENE S，ROBBINS Y，MYDLARZ W K，et al.Inhibition of MDSC trafficking with SX-682，a CXCR1/2 inhibitor，enhances NK-Cell immunotherapy in head and neck cancer models［J］.Clin Cancer Res，2020，26 （6）：1420-1431.
  34. 34.
    HUINEN Z R，HUIJBERS E，VAN BEIJNUM J R，et al.Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes［J］.Nat Rev Clin Oncol，2021，18 （8）：527-540.
  35. 35.
    LI Y F，WANG J，ZHANG Q.Clinical effect of leuprolide combined with huoxue huayu method on pre-menopausal uterine fibroids，endometrial COX-2 VEGF expression and microvessel density［J］.Chin Arch Tradit Chin Med，2018，36（8）：1950-1953.
  36. 36.
    ZHOU D，XIE L.Clinical study of guizhi Fulingwan combined with PD-1 in the treatment of advanced ovarian cancer［J］.Elec J Pract Gynecol Endocrinol，2024，11（2）：68-70.
  37. 37.
    GULIJIAMILA S，NUERBIYA Y.Adverse drug reactions and prevention measures of anti-tumor drugs［J］.Smart Healthcare，2019，5（22）：177-178.
  38. 38.
    HUANG L Y.The effect of traditional Chinese medicine nursing intervention on gastrointestinal reactions in cancer chemotherapy patients［J］.J Qilu Nurs，2012，18（22）：63-64.
  39. 39.
    SU H，LI Z G，WANG Y Y.The incidence and influencing factors of bone marrow suppression in elderly patients with colorectal cancer after chemotherapy［J］.Chin J Gerontol，2021，41（20）：4391-4394.
  40. 40.
    WANG M Z，CHEN S，CHEN Y H，et al.The occurrence and influencing factors of bone marrow suppression in elderly lung cancer patients undergoing chemotherapy［J］.Chin J Gerontol，2021，41（10）：2209-2212.
  41. 41.
    XIAO X T，WANG X，WANG Y，et al.The best evidence summary for prevention and nursing care of chemotherapy-induced alopecia in breast cancer patients［J］.Chin J Nurs，2021，56（7）：1072-1078.
  42. 42.
    ZHOU S，QU Y Z，ZHANG L，et al.Study on statu quo of body image of gynecological cancer patients undergoing chemotherapyafter surgery and its influencing factors［J］.Chin Nurs Res，2021，35（2）：306-310.
  43. 43.
    GUO Y Z，SUN S X.Clinical analysis of skin damage in acute leukemia［J］.J Leuk Lymphoma，2005，14（4）：230.
  44. 44.
    LI Y.Nursing of preventing nephrotoxicity in gynecological cisplatin chemotherapy patients［J］.Chin J Nurs，2001，36（12）：919-921.
  45. 45.
    XUE C，WANG X H，FU R.Application value of serum cTnI combined with BNP detection in early prediction of chemotherapy-related cardiotoxicity in breast cancer［J］.J Mod Oncol，2021，29（8）：1339-1343.
  46. 46.
    QUAN L，ZHANG Y D，ZHAO J，et al.Possible mechanisms and interventions of cardiotoxicity induced by chemotherapeutic drugs in cancer patients［J］.Int J Cardiovasc Dis，2021，48（2）：98-101.
  47. 47.
    ZHANG X Y，ZHOU L S.Nursing care of chemotherapy drug extravasation through veins［J］.Chin J Gerontol，2014，34（12）：3502-3504.
  48. 48.
    FENG F M，ZHANG W Y，WANG X Y，et al.Research on symptom clusters in patients with gastrointestinal cancer during chemotherapy based on different symptom experiences［J］.Chin Gener Pract Nurs，2021，19（29）：4033-4038.
  49. 49.
    GENG J Z.How to relieve constipation in chemotherapy patients［J］.Cancer Front，2021（3）：34-35.
  50. 50.
    TAN M.Clinical observation on the treatment of 28 cases of oophoroma with GuizhiFulingwan and adjuvant chemotherapy［J］.Anti-tumor Pharm，2011，1（6）：520-523.
  51. 51.
    LI J R.Effect of Guizhi Fuling capsule and earthw orm combined with TC regimen on CA125 and quality of life of blood stasis type of ovarian cancer［D］.Harbin：Heilongjiang University of Chinese Medicine，2016.
  52. 52.
    YANG Y，XIONG L F，ZOU J，et al.Observation of the short term efficacy of Guizhi Fulingwan combined with platinum in the treatment of advanced ovarian cancer［J］.World Chin Med，2017，12（A02）：157.
  53. 53.
    ZHAO L.Observe the clinical effects：Changes of hemodynamic indexes by the treatment of a combination of "Guizhi Fuling capsules" with lumbricis and TC chemotherapy to the ovarian cancer pauents who belong to blood stasis type and have accepted surgery［D］.Harbin：Heilongjiang University of Chinese Medicine，2016.
  54. 54.
    LIAO X Q，KUANG S S.Effects of incentive nursing combined with diversified psychological counseling on coping style of patients with ovarian cancer［J］.China Med Pharm，2020，10（6）：123-125，129.
  55. 55.
    MANNE S L，MYERS-VIRTUE S，KISSANE D，et al.Group-based trajectory modeling of fear of disease recurrence among women recently diagnosed with gynecological cancers［J］.Psychooncology，2017，26 （11）：1799-1809.
  56. 56.
    HINZ A，MEHNERT A，ERNST J，et al.Fear of progression in patients 6 months after cancer rehabilitation-a- validation study of the fear of progression questionnaire FoP-Q-12［J］.Support Care Cancer，2015，23 （6）：1579-1587.
  57. 57.
    GUO T T，XING W，GUO L Y，et al.Coping style and quality of life of ovarian cancer patients：The moderating role of fear of progression［J］.Mod Prevent Med，2020，47（10）：1803-1806.
  58. 58.
    WANG Y，MA T Y，GAO Y Y.Relationship between cancer-caused fatigue，psychological consistency and quality of life in ovarian cancer patients［J］.Health Edu Health Prom，2023，18（1）：20-24.
  59. 59.
    XU L，CHEN M.20 cases of advanced ovarian cancer treated with modified Guizhi Fulingwan combined with DP regimen［J］.Mod Chin Med，2011，31（2）：11-14.
  60. 60.
    HUANG X Y.Guizhi Fulingwan combined with western medicine on advanced ovarian cancer［J］.Shaanxi J Tradit Chin Med，2017，38（5）：643-645.

Leer el texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website